Progress for Angelman Syndrome Relies on a Strong NIH and FDA
Angelman syndrome research is at a turning point, and federal cuts could put that progress at risk. FAST and ASF are urging congressional leaders to protect the NIH and FDA expertise that helps move treatments safely to families.
2025 AS Congressional Advocacy Day: Legislative Priorities
Ahead of the second Angelman Syndrome Advocacy Day, FAST and ASF outline key 2025 priorities: protecting NIH research funding, safeguarding Medicaid, and supporting caregiver legislation.
The National Institutes of Health awarded the first phase of a roughly $40M grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases
In October 2023, the National Institutes of Health awarded the first phase of a roughly $40m grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases. The two diseases being targeted in the project are Angelman syndrome and H1-4 (HIST1H1E) syndrome. The project team named under […]